VTVT vTv Therapeutics

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025.

Conference details are as follows:

H.C. Wainwright “HCW@Home with vTv Therapeutics”

Format: Fireside Chat

Moderator: Emily Bodnar, Director, H.C. Wainwright

vTv Therapeutics Speakers:

  • Paul Sekhri, Chairman of the Board, President & Chief Executive Officer
  • Thomas Strack, MD, Chief Medical Officer
  • Carmen Valcarce, Ph.D., Executive Vice President, Chief Scientific Officer
  • Michael Tung, MD, MBA, Chief Financial Officer

Date: Thursday, June 12, 2025

Time: 10:00 AM ET

Webcast Link: Register

The webcast of the event will be accessible from News & Events page of the vTv website.

About vTv Therapeutics

vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules into different indications for chronic diseases. Learn more at  or follow the company on  or .

Investor Contact

John Fraunces

LifeSci Advisors, LLC

917-355-2395

Media Contact

Caren Begun

TellMed Strategies

201-396-8551



EN
11/06/2025

Underlying

VTVTvTv Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on vTv Therapeutics

 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Pro...

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update •   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 •   Cadisegliatin intellectual property portfolio expanded •   Leadership team strengthened HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being...

August 12, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegl...

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cad...

August 11, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Announces First Study Participant Randomized in CATT1...

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes Topline results from CATT1 Phase 3 trial expected in second half of 2026 HIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced the first study participant has been randomized in the Company’s CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treatment to insulin in adults with t...

August 7, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Seri...

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025. Conference details are as follows: H.C. Wainwright “HCW@Home with vTv Therape...

June 11, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial ...

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical indu...

May 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch